GelTex Pharmaceuticals

GelTex Pharmaceuticals develops and markets non-absorbed polymeric drugs that can bind and remove target substances within the gastrointestinal tract. It also develops small-molecule drugs composed of novel polyamine analogs and metal chelators. Its key focus areas include hyperphosphatemia, hypercholesterolemia, cancer, iron overload, and infectious diseases. As of December 14, 2000, GelTex Pharmaceuticals was acquired by Genzyme Corp.